A review of cost-effectiveness analysis: From theory to clinical practice

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
ROCCA, Hans-Peter Brunner-La
LIMA, Antonio Carlos Pedroso de
Citação
MEDICINE, v.102, n.42, article ID e35614, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cost-effectiveness analysis has long been practiced; registries date back to the United States of America War Department in 1886. In addition, everyone does intuitive cost-effectiveness analyses in their daily lives. In routine medical care, health economic assessment becomes increasingly important due to progressively limited resources, rising demands, population increases, and continuous therapeutic innovations. The health economic assessment must analyze the outcomes and costs of actions and technologies as objectively as possible to guarantee efficient assessment of novel interventions for Public Health Policy. In other words, it is necessary to determine how much society or patients are willing to or able to pay for novel interventions compared with existing alternatives, given the available resources. In addition, increased cost may displace other health care services already provided in case of fixed budget health care systems. To conduct such analyses, researchers must use standard methodologies and interpretations in light of regional characteristics according to social and economic determinants as well as clinical practice. Such an approach may be essential for transforming the current healthcare system to a value-based model. In this narrative review, concepts of the importance of and some approaches to health economic evaluation in clinical practice will be discussed.
Palavras-chave
bootstrapping and health policy, cost-effectiveness analysis, cost-utility analysis, health economics, QALY
Referências
  1. Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z
  2. Baltussen RMPM, 2002, INT J TECHNOL ASSESS, V18, P112
  3. Bodrogi J, 2010, BRIT J PHARMACOL, V159, P1367, DOI 10.1111/j.1476-5381.2009.00550.x
  4. Brasil. Ministerio da Saude. Secretaria de Ciencia Tecnologia e Insumos Estrategicos, 2014, Diretrizes metodologicas: diretriz de avaliacao economica
  5. BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206
  6. Briggs A., 2006, Decision Modelling for Health Economic Evaluation, VFirst ed, P256
  7. Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W
  8. Briggs AH, 1999, STAT MED, V18, P3245, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2
  9. Briongos-Figuero S, 2020, ESC HEART FAIL, V7, P280, DOI 10.1002/ehf2.12548
  10. Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.3.CO;2-N
  11. Chapko MK, 2009, HEALTH ECON, V18, P1188, DOI 10.1002/hec.1422
  12. Cylus J., 2018, Health Systems for Prosperity and Solidarity Policy brief. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies
  13. Dieleman JL, 2017, JAMA-J AM MED ASSOC, V318, P1668, DOI 10.1001/jama.2017.15927
  14. Docherty KF, 2017, EUR HEART J, V38, P338, DOI 10.1093/eurheartj/ehw427
  15. Drummond MF., 2006, Methods for the Economic Evaluation of Health Care Programmes, V3rd ed. Thrid ed, P464
  16. Drummond MF., 1980, Principles of Economic Appraisal in Health Care, P148
  17. Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903
  18. Fonarow GC, 2019, JAMA CARDIOL, V4, P691, DOI 10.1001/jamacardio.2019.1647
  19. Gold MR., 1996, COST EFFECTIVENESS H, DOI 10.1093/acprof:oso/9780190492939.001.0001/acprof-9780190492939
  20. Brandao SMG, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0158-z
  21. Gray AM., 2010, Applied methods of cost-effectiveness analysis in Healthcare
  22. Greene SJ, 2018, CIRCULATION, V138, P1039, DOI 10.1161/CIRCULATIONAHA.118.034668
  23. Gurwitz JH, 2020, JAMA CARDIOL, V5, P247, DOI 10.1001/jamacardio.2019.5233
  24. Hutubessy RCW, 2001, HEALTH ECON, V10, P473, DOI 10.1002/hec.614
  25. Khatana SAM, 2019, JAMA CARDIOL, V4, P671, DOI 10.1001/jamacardio.2019.1651
  26. Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944
  27. MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230
  28. Mccarthy J., 2019, Seven in 10 maintain negative view of U.S. healthcare system: gallup poll social series
  29. Meltzer MI, 2001, LANCET, V358, P993, DOI 10.1016/S0140-6736(01)06107-4
  30. Mooney CZ., 1993, Bootstrapping: a non-parametric approach to statistical inference, VFirst ed, P80
  31. National Institute for Health and Clinical Excellence, 2013, Guide to the methods of technology appraisal
  32. Neumann PJ, 2000, ANNU REV PUBL HEALTH, V21, P587, DOI 10.1146/annurev.publhealth.21.1.587
  33. Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150
  34. Quade ES., 1971, A History of Cost-Effectiveness, P1
  35. Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901
  36. Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
  37. Simoens S, 2010, INT J ENV RES PUB HE, V7, P1835, DOI 10.3390/ijerph7041835
  38. Stevens A, 2003, J PUBLIC HEALTH MED, V25, P98, DOI 10.1093/pubmed/fdg022
  39. Tan SS, 2009, EUR J HEALTH ECON, V10, P39, DOI 10.1007/s10198-008-0101-x
  40. The World Bank Report, International comparison program (ICP)
  41. U. S. Environmental Protection Agency (EPA), 2014, Guidelines for preparing economic analyses
  42. WAKKER P, 1995, HEALTH ECON, V4, P373, DOI 10.1002/hec.4730040503
  43. Whitehead SJ, 2010, BRIT MED BULL, V96, P5, DOI 10.1093/bmb/ldq033
  44. Zhao H., 2000, Estimating mean quality adjusted lifetime with censored data
  45. Zhao HW, 1999, BIOMETRICS, V55, P1101, DOI 10.1111/j.0006-341X.1999.01101.x